Our overall hypothesis was that biomarkers such as accelerated gastric emptying of solids in obesity may influence the response to GLP-1 agonists such as exenatide or liraglutide, which are being tested as weight loss remedies in obesity (Bray and Ryan 2014). This evidence concerns the gene GCG and Obesity.